Maria Materozzi

Maria Materozzi

Auto-generated profile, based on publicly available information

Maria Materozzi

Department of Medicine Surgery and Neurosciences, University of Siena, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2016 in PPAR Research
Verified
Journal Article
Open access
PDF file
TMTommaso Mello
Tommaso Mello
MMMaria Materozzi
Maria Materozzi
AGAndrea Galli
Andrea Galli
Metabolic related diseases, such as type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD), are widespread threats which bring about a significant burden of deaths worldwide, mainly due to cardiovascular events and cancer. The pathogenesis of these diseases is extremely complex, multifactorial, and only partially understood. As the main metabolic organ, the liver is central to maintain whole body energetic homeostasis. At the cellular level, mitochondria are the metabolic hub connecting and integrating all the main biochemical, hormonal, and inflammatory signaling pathways to fulfill the energetic and biosynthetic demand of the cell. In the liver, mitochondria metabolism needs to cope with the energetic regulation of the whole body. The nuclear receptors PPARs orchestrate lipid and glucose metabolism and are involved in a variety of diseases, from metabolic disorders to cancer. In this review, focus is placed on the roles of PPARs in the regulation of liver mitochondrial metabolism in physiology and pathology, from NAFLD to HCC.

6 May 2018 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
MMMaria Materozzi
Maria Materozzi
DMDaniela Merlotti
Daniela Merlotti
LGLuigi Gennari
Luigi Gennari
SBSimone Bianciardi
Simone Bianciardi
Osteoporosis is the most common metabolic bone disorder affecting up to 40% of postmenopausal women, characterized by a reduction in bone mass and strength leading to bone fragility and fractures. Despite the available tools for diagnosis and stratification of a fracture risk, bone loss occurs insidiously and osteoporosis is often diagnosed after the first fracture has occurred, with important health-related outcomes. Therefore, the need of markers that could efficiently diagnose bone fragility and osteoporosis is still necessary. Over the past few years, novel studies have focused on miRNAs, small noncoding RNAs that are differentially expressed in many pathological conditions, making them attractive biomarkers. To date, the role of miRNAs in bone disorders remains in great part unclear. In particular, limited and partly conflicting information is available concerning their use as potential biomarkers for osteoporosis, due to differences in patient selection, type of samples, and analytical methods. Despite these limits, concordant information about some specific miRNAs is now arising, making likely their use as additional tools to stratify the risk of osteoporosis and possibly fractures. In this review, we summarize the most relevant studies concerning circulating miRNAs differentially expressed in osteoporotic patients along with their function in bone cells and bone turnover.

11 May 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
Daniela MerlottiDaniela Merlotti
Daniela Merlotti
MMMaria Materozzi
Maria Materozzi
SBSimone Bianciardi
Simone Bianciardi
VGVito Guarnieri
Vito Guarnieri
DRDomenico Rendina
Domenico Rendina
Luigi GennariLuigi Gennari
Luigi Gennari
Context Paget’s disease of bone (PDB) is a metabolic bone disease, whose genetic cause remains unknown in up to 50% of familial cases. Objective Our aim was to investigate the underlying genetic defect in a large pedigree with a severe, early onset, autosomal dominant form of PDB across three generations. Methods Whole exome sequencing was performed in affected and unaffected family members, and then mutation screening was replicated in a sample of PDB cases with early-onset, polyostotic PDB. Results We identified a frameshift D107Rfs*3 mutation in PFN1 (encoding for profilin1, a highly conserved regulator of actin-polymerization and cell motility) causing the truncation of the C-terminal part of the protein. The mutation was also detected in a 17-yrs old asymptomatic family member that upon biochemical and radiological analyses was indeed found to be affected. Sequencing of the entire PFN1 coding region in unrelated PDB cases identified the same mutation in one patient. All mutation carriers had a reduced response to bisphosphonates, requiring multiple zoledronate infusions to control bone pain and achieve biochemical remission over a long term. In vitro osteoclastogenesis in PBMCs from mutation carriers showed a higher number of osteoclasts with PDB-like features. A similar phenotype was observed upon PFN1 silencing in murine bone marrow-derived monocytes, suggesting that the frameshift PFN1 mutation confers a loss of function in profilin 1 activity that induces PDB-like features in the osteoclasts, likely due to enhanced cell motility and actin ring formation. Conclusions Our findings indicate that PFN1 mutation causes an early onset, polyostotic PDB-like disorder.

12 November 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
TMTommaso Mello
Tommaso Mello
MMMaria Materozzi
Maria Materozzi
FZFrancesca Zanieri
Francesca Zanieri
ISIrene Simeone
Irene Simeone
ECElisabetta Ceni
Elisabetta Ceni
AGAndrea Galli
Andrea Galli

21 October 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
Daniela MerlottiDaniela Merlotti
Daniela Merlotti
DRDomenico Rendina
Domenico Rendina
RMRiccardo Muscariello
Riccardo Muscariello
TPTommaso Picchioni
Tommaso Picchioni
MAMario Alessandri
Mario Alessandri
Luigi GennariLuigi Gennari
Luigi Gennari
Context Intravenous aminobisphosphonates (N-BPs) can induce an acute phase reaction (APR) in up to 40% to 70% of first infusions, causing discomfort and often requiring intervention with analgesics or antipyretics. Objective Our aim was to explore the risk factors of APR in a large sample of patients with Paget’s disease of bone (PDB) and to assess the possible preventive effects of vitamin D administration. Methods An observational analysis was performed in 330 patients with PDB at the time of N-BP infusion. Then, an interventional study was performed in 66 patients with active, untreated PDB to evaluate if vitamin D administration (oral cholecalciferol 50 000 IU/weekly for 8 weeks before infusion) may prevent APR. Results In a retrospective study, APR occurred in 47.6% and 18.3% of naive or previously treated patients, respectively. Its prevalence progressively increased in relation to the severity of vitamin D deficiency, reaching 80.0% in patients with 25-hydroxyvitamin D (25OHD) levels below 10 ng/mL (relative risk (RR) = 3.7; 95% confidence interval (CI) 2.8–4.7, P < .0001), even in cases previously treated with N-BPs. Moreover, APR occurred more frequently in patients who experienced a previous APR (RR = 2.8; 95% CI 1.5–5.2; P < .001) or in carriers of SQSTM1 mutation (RR = 2.3; 95% CI 1.3–4.2; P = .005). In the interventional study, vitamin D supplementation prevented APR in most cases, equivalent to a RR of 0.31 (95% CI 0.14–0.67; P < .005) with respect to prevalence rates of the observational cohort. A similar trend was observed concerning the occurrence of hypocalcemia. Conclusions The achievement of adequate 25OHD levels is recommended before N-BP infusion in order to minimize the risk of APR or hypocalcemia in PDB.

23 July 2018 in Expert Opinion on Orphan Drugs
Verified
Journal Article
Closed access
Luigi GennariLuigi Gennari
Luigi Gennari
DRDomenico Rendina
Domenico Rendina
TPTommaso Picchioni
Tommaso Picchioni
SBSimone Bianciardi
Simone Bianciardi
MMMaria Materozzi
Maria Materozzi
Daniela MerlottiDaniela Merlotti
Daniela Merlotti
Introduction: Paget’s disease of bone (PDB) is a chronic bone disorder, which affects middle-aged or older adults and results in enlarged and deformed bones in one or more skeletal regions. Family history has been reported in up to 40% of cases, suggesting a consistent genetic predisposition . At affected sites, the characteristic feature of PDB is an increased resorption followed by an increased bone formation, producing a disorganized and structurally abnormal bone. Consequently, bone pain, arthritis, deformities, and fractures can occur. In less than 1%, neoplastic degeneration in osteosarcoma, or giant cell tumor has been described at PDB sites. Areas covered: We provide a contemporary overview of the epidemiology, pathogenesis and treatment of PDB. Expert opinion: While recent epidemiological evidence indicates a decreasing prevalence and severity of PDB, over the past two decades there have been consistent advances on the genetic mechanisms of PDB. It is now clear that PDB is a genetically heterogeneous disorder, with at least three different genes (SQSTM1, ZNF687, FKBP5) involved in the classic form and four additional genes identified in PDB-related syndromes. The clinical management of PDB has also evolved, with the development of the most potent aminobisphosphonate, zoledronic acid, which allows long-term remission in the majority of patients.